Eli Lilly antibody drug fails in a COVID-19 study; other studies go on
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t…
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t…
I’m excited to join this incredible initiative! This organization’s mission is very important to me and I’m proud to help them make a difference. Please…
About the Oncology Center of Excellence
In honor of our 30th anniversary, we’re catching up with former grant recipients to hear how their work has impacted kidney cancer care and research.
Led by Dr. Kathleen Mahoney in collaboration with Dr. Rupal Bhatt, both clinicians and scientists, and Dr. Gordon Freeman, a virologist and immunologist who contributed…
Dr. Toni Choueiri and Dr. Rizwan Romee received a 2021 Advanced Discovery Award for their project “Adoptive cytokine-induced memory-like NK cell therapy
We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of t…
AbstractThe phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax)…
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving…
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy…